Jason Matuszewski - 07 Oct 2026 Form 4 Insider Report for BioStem Technologies, Inc. (BSEM)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: BSEM
Reported as of: 07 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Oct 2026, 16:30:03 UTC
Prior SEC filing: 17 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Katherine Gorrell, Attorney-in-Fact

Filing notes and source

Key filing fact

Jason Matuszewski filed Form 4 for BioStem Technologies, Inc. (BSEM) on 09 Oct 2026.

Key facts

This page summarizes Jason Matuszewski's Form 4 filing for BioStem Technologies, Inc. (BSEM).
2 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 09 Oct 2026, 16:30.

Change

Previous filing in this sequence was filed on 17 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001634730 Primary reporting owner

Matuszewski Jason

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O BIOSTEM TECHNOLOGIES, INC., 2836 CENTER PORT CIRCLE, POMPANO BEACH
Signature: /s/ Katherine Gorrell, Attorney-in-Fact
Signature date: 09 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSEM transaction

Common Stock

Options Exercise

Transaction value
Shares: +250,000
Change %: +19%
Price: $2.00^*
Shares after: 1,553,551
Date: 07 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSEM transaction Derivative

Options (Right to Buy)

Options Exercise

Transaction value
Shares: -250,000
Change %: -11%
Price: $0.000000^*
Shares after: 2,000,000
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $2.00
Footnotes: F5

BSEM holding Derivative

Series A-1 Convertible Preferred Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100
Exercise price
Footnotes: F2, F3, F4

BSEM holding Derivative

Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 198,807
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 198,807
Exercise price: $10.05
Footnotes: F6

BSEM holding Derivative

Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,427
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,427
Exercise price: $10.05
Footnotes: F7

BSEM holding Derivative

Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 440,529
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 440,529
Exercise price: $5.50
Footnotes: F8

BSEM holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 33,874
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,874
Exercise price
Footnotes: F9, F10

BSEM holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 99,901
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 99,901
Exercise price
Footnotes: F1, F9, F11

BSEM holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 363,636
Date: 07 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 363,636
Exercise price
Footnotes: F9, F12

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 12 footnotes

Footnote F1

The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error.

Footnote F2

The Series A-1 Convertible Preferred Shares is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.

Footnote F3

The Series A-1 Convertible Preferred Shares have no expiration date.

Footnote F4

Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.

Footnote F5

These options are fully vested and exercisable.

Footnote F6

These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

Footnote F7

These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

Footnote F8

These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

Footnote F9

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F10

These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).

Footnote F11

These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

Footnote F12

These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .